Bipolar disorder is a mental illness characterized by episodes of mood elevation (mania or hypomania) and depression that can significantly affect functioning.
Advances in precision mental health research include TMS findings published in Nature Molecular Psychiatry showing targeted brain stimulation can address specific depression and anxiety symptoms, the launch of the three-year GlobalMinds NHS genomic study analyzing 49,000 DNA samples, and the new $1 million Wellcome Prize for Mental Health Science.
Evidence on ketogenic diets remains limited for psychiatric disorders and diabetes, while a systematic review in overweight and obese women with PCOS found significant short-term improvements. Experts said more controlled, long-term studies are needed.
A large Kaiser Permanente study of 463,396 adolescents found those using cannabis were twice as likely to develop psychotic or bipolar disorders, with elevated risks for depression and anxiety. The research suggests adolescence is a vulnerable period for cannabis-related mental health harms, though causality remains complex.
The FDA approved BYSANTI (milsaperidone) for bipolar I disorder and schizophrenia in adults, and accepted Vanda's BLA filing for imsidolimab to treat Generalized Pustular Psoriasis with a target action date of December 12, 2026.
Vanda Pharmaceuticals announced FDA approval for BYSANTI tablets to treat Bipolar I manic episodes and schizophrenia in adults. The drug has patent protection extending to 2044 and will be commercially available in Q3 2026.
The FDA has approved BYSANTI (milsaperidone), a new chemical entity for treating bipolar I disorder and schizophrenia in adults. The drug is Vanda's second approval in less than two months and is expected to launch in Q3 2026.
The U.S. Food and Drug Administration has approved Vanda Pharmaceuticals' Bysanti for treating schizophrenia and acute bipolar I disorder. The company expects to launch the drug in the third quarter of 2026.
Vanda Pharmaceuticals received FDA approval for Bysanti (milsaperidone), an atypical antipsychotic for schizophrenia and manic or mixed episodes in bipolar I disorder. The drug will be available by the third quarter of 2026.
Researchers identified shared white matter alterations in the corpus callosum as a common biomarker across schizophrenia and bipolar disorder, supporting the concept of a psychosis spectrum rather than distinct disorders.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07592884 |
Rochester Forensic Assertive Community Treatment Model in Minnesota |
COMPLETED | NA |
| NCT07570875 |
Evaluating the Impact of Ketogenic Therapy on Symptom Severity and Metabolic Side Effect Profile Among Individuals Living With Bipolar Disorder in A Rural Southern Catchment Area |
NOT_YET_RECRUITING | NA |
| NCT07556861 |
A Study Of Senyo Health With Comorbid Alcohol Use Disorder Treatment In Bipolar Patients |
NOT_YET_RECRUITING | NA |
| NCT07549581 |
A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode |
COMPLETED | PHASE1 |
| NCT07548359 |
Psychiatric Nursing Intervention for Caregivers of Patients With Bipolar Disorder |
COMPLETED | NA |
| NCT07534475 |
Venous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT |
NOT_YET_RECRUITING | NA |
| NCT07503275 |
Functional Magnetic Resonance Imaging Study of Inhibitory Control in Bipolar Disorder and Major Depressive Disorder |
NOT_YET_RECRUITING | NA |
| NCT07479758 |
Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment Outcomes of Severe Mental Disorders |
RECRUITING | |
| NCT07472920 |
Empagliflozin Adjunctive Therapy in Bipolar Depression |
NOT_YET_RECRUITING | NA |
| NCT07444463 |
Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications |
NOT_YET_RECRUITING | NA |
